Human Xtensions Ltd. (HUMX.TA)

ILA 35.1

(0.0%)

EBITDA Summary of Human Xtensions Ltd.

Human Xtensions Ltd.'s latest annual EBITDA in 2023 was -34.54 Million ILS , up 16.53% from previous year.
Human Xtensions Ltd.'s latest quarterly EBITDA in 2024 Q2 was -6.23 Million ILS , down 0.0% from previous quarter.
Human Xtensions Ltd. reported an annual EBITDA of -41.38 Million ILS in 2022, up 17.82% from previous year.
Human Xtensions Ltd. reported an annual EBITDA of -50.33 Million ILS in 2021, down -92.11% from previous year.
Human Xtensions Ltd. reported a quarterly EBITDA of -6.23 Million ILS for 2024 Q1, up 20.84% from previous quarter.
Human Xtensions Ltd. reported a quarterly EBITDA of -9.87 Million ILS for 2023 Q1, up 4.28% from previous quarter.

Annual EBITDA Chart of Human Xtensions Ltd. (2023 - 2018)

Historical Annual EBITDA of Human Xtensions Ltd. (2023 - 2018)

Year	EBITDA	EBITDA Growth
2023	-34.54 Million ILS	16.53%
2022	-41.38 Million ILS	17.82%
2021	-50.33 Million ILS	-92.11%
2020	-26.01 Million ILS	44.12%
2019	-46.84 Million ILS	-66.46%
2018	-28.18 Million ILS	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-6.23 Million ILS	0.0%
2024 Q1	-6.23 Million ILS	20.84%
2023 Q1	-9.87 Million ILS	4.28%
2023 Q3	-7.57 Million ILS	17.8%
2023 FY	- ILS	16.53%
2023 Q2	-9.21 Million ILS	6.69%
2023 Q4	-7.87 Million ILS	-3.93%
2022 Q3	-10.45 Million ILS	-18.32%
2022 Q2	-8.83 Million ILS	25.05%
2022 Q1	-11.78 Million ILS	4.44%
2022 FY	- ILS	17.82%
2022 Q4	-10.31 Million ILS	1.25%
2021 FY	- ILS	-92.11%
2021 Q4	-12.33 Million ILS	-1.9%
2021 Q3	-12.1 Million ILS	11.69%
2021 Q2	-13.7 Million ILS	-21.72%
2021 Q1	-11.25 Million ILS	5.2%
2020 Q2	-5.27 Million ILS	0.0%
2020 Q1	-5.27 Million ILS	62.81%
2020 Q3	-4.07 Million ILS	22.76%
2020 FY	- ILS	44.12%
2020 Q4	-11.87 Million ILS	-191.58%
2019 Q1	-9.54 Million ILS	0.0%
2019 FY	- ILS	-66.46%
2019 Q4	-14.17 Million ILS	-0.56%
2019 Q3	-14.1 Million ILS	-47.72%
2019 Q2	-9.54 Million ILS	0.0%
2018 FY	- ILS	0.0%

Peer EBITDA Comparison of Human Xtensions Ltd.

Name	EBITDA	EBITDA Difference